Voyager Therapeutics Granted U.S. Patent AADC Polynucleotides For The Treatment Of Parkinson's Disease
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics has been granted a U.S. patent for AADC polynucleotides, which are used in the treatment of Parkinson's disease.
September 19, 2023 | 5:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The granting of the U.S. patent for AADC polynucleotides to Voyager Therapeutics could potentially strengthen the company's position in the Parkinson's disease treatment market.
The granting of a patent is a significant event for a biotech company like Voyager Therapeutics. It provides the company with exclusive rights to the patented technology, in this case, AADC polynucleotides for the treatment of Parkinson's disease. This could potentially give Voyager a competitive edge in the market, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100